AbbVie (ABBV) Gross Margin Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Gross Margin Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
531.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-168.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
449.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
134.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-367.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
129.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-1,698.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-714.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
449.00 |
| Dec 31, 2025 |
19.00 |
| Sep 30, 2025 |
28.00 |
| Jun 30, 2025 |
42.00 |
| Mar 31, 2025 |
-6.00 |
| Dec 31, 2024 |
-9.00 |
| Sep 30, 2024 |
148.00 |
| Jun 30, 2024 |
335.00 |
| Mar 31, 2024 |
-87.00 |
| Dec 31, 2023 |
-609.00 |
| Sep 30, 2023 |
-742.00 |
| Jun 30, 2023 |
502.00 |
| Mar 31, 2023 |
-1,007.00 |
| Dec 31, 2022 |
-453.00 |
| Sep 30, 2022 |
-1,126.00 |
| Jun 30, 2022 |
-656.00 |
| Mar 31, 2022 |
-829.00 |
| Dec 31, 2021 |
-467.00 |
| Sep 30, 2021 |
-833.00 |
| Jun 30, 2021 |
-904.00 |
| Mar 31, 2021 |
-809.00 |
| Dec 31, 2020 |
-433.00 |
| Sep 30, 2020 |
-1,604.00 |
| Jun 30, 2020 |
-1,358.00 |
| Mar 31, 2020 |
219.00 |
| Dec 31, 2019 |
-18.00 |
| Sep 30, 2019 |
74.00 |
| Jun 30, 2019 |
-26.00 |
| Mar 31, 2019 |
134.00 |
| Dec 31, 2018 |
-130.00 |
| Sep 30, 2018 |
-265.00 |
| Jun 30, 2018 |
83,271.00 |
| Mar 31, 2018 |
-560.00 |
| Dec 31, 2017 |
-895.00 |
| Sep 30, 2017 |
-131.00 |
| Jun 30, 2017 |
58.00 |
| Mar 31, 2017 |
-61.00 |
| Dec 31, 2016 |
222.00 |
| Sep 30, 2016 |
6.00 |
| Jun 30, 2016 |
69.00 |
| Mar 31, 2016 |
366.00 |
| Dec 31, 2015 |
125.00 |
| Sep 30, 2015 |
286.00 |
| Jun 30, 2015 |
-83,219.00 |
| Mar 31, 2015 |
901.00 |